Related Experiment Video
Updated: Sep 26, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Well differentiated papillary mesothelial tumor: a new name and new problems
Andrew Churg1, Francoise Galateau-Salle2
1Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada. achurg@mail.ubc.ca.
Abstract:
Well-differentiated papillary mesothelial tumor (WDPMT, formerly called well-differentiated papillary mesothelioma) is a morphologically distinctive lesion composed of expansile papillae with a myxoid core covered by a single layer of generally bland mesothelial cells. Whether some WDPMT are precursors of invasive mesothelioma is uncertain, and this question is confounded by shallow biopsies of ordinary diffuse mesotheliomas that have superficial areas resembling WDPMT as well as by misinterpretation of some cases of mesothelioma in situ. Genetic analyses on a very small number of published cases of peritoneal WDPMT have shown a variety of mutations/copy number losses that do not overlap at all with those that are found recurrently in invasive mesotheliomas. The newly described entity of mesothelioma in situ usually appears as a single layer of mesothelial cells that have lost BAP1 by immunostaining, but sometimes is papillary and produces a morphologic mimic of WDPMT. We propose that, at least in the peritoneal cavity where most WDPMT occur, there are two morphologically identical but functionally distinct lesions: one is true WDPMT, a process that is probably benign, and the other is papillary mesothelioma in situ with the configuration of WDPMT. For that reason immunostaining for BAP1, and if necessary MTAP or CDKN2A FISH, should always be performed on cases with the appearance of WDPMT. It is possible, but speculative, that the small number of reports in the literature which describe invasive mesothelioma arising from WDMPT are actually describing invasive mesothelioma arising from mesothelioma in situ that looks like WDPMT.
Insights
Well-differentiated papillary mesothelial tumor (WDPMT) may be distinct from invasive mesothelioma. Distinguishing WDPMT from papillary mesothelioma in situ is crucial, necessitating specific diagnostic tests like BAP1 immunostaining.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Well-differentiated papillary mesothelial tumor (WDPMT) is a distinct lesion.
- Its relationship to invasive mesothelioma is uncertain.
- Genetic profiles of WDPMT differ from invasive mesotheliomas.
Purpose of the Study:
- To differentiate true WDPMT from morphologically similar lesions.
- To clarify the precursor role of WDPMT in invasive mesothelioma.
- To establish diagnostic criteria for distinguishing these entities.
Main Methods:
- Morphological analysis of mesothelial lesions.
- Genetic analysis (mutations, copy number losses) of WDPMT.
- Immunohistochemical staining (BAP1) and FISH (MTAP, CDKN2A) for diagnostic distinction.
Main Results:
- WDPMT shows distinct genetic alterations compared to invasive mesotheliomas.
- Papillary mesothelioma in situ can mimic WDPMT morphologically.
- BAP1 loss is a key feature in distinguishing these lesions.
Conclusions:
- WDPMT is likely a benign process, separate from invasive mesothelioma.
- Papillary mesothelioma in situ can present with WDPMT morphology.
- Diagnostic immunostaining for BAP1 and potentially FISH for MTAP/CDKN2A are essential for accurate diagnosis.
More Related Videos
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024